Mesenchymal stem cell therapy for neurological disorders - Medipost

Drug Profile

Mesenchymal stem cell therapy for neurological disorders - Medipost

Alternative Names: Neurostem; Neurostem-AD

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator Medipost
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Alzheimer's disease
  • Preclinical Amyotrophic lateral sclerosis; Stroke

Most Recent Events

  • 31 Aug 2016 Medipost's Mesenchymal stem cell therapy is still in phase I/II trials for Alzheimer's disease in South Korea (Intraventricular)
  • 28 Feb 2014 Phase-I/II clinical trials in Alzheimer's disease in South Korea (Intraventricular)
  • 31 Mar 2012 Duk Lyul Na (in collaboration with Medipost) initiates enrolment in a follow-up phase I trial for Alzheimer's disease in South Korea (NCT01696591)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top